New CAR t therapy targets hidden leukemia cells in adults
NCT ID NCT05535855
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new type of immunotherapy (CAR T cells) in adults with B-cell acute lymphoblastic leukemia (B-ALL) who still have tiny amounts of cancer cells after their first round of treatment. The goal is to see if the therapy is safe and can eliminate these leftover cells to prevent relapse. About 29 participants will receive the treatment and be monitored for side effects and how well the cancer responds.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Colorado Hospital
RECRUITINGAurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can donor immune cells tame stem cell transplant risks?
- Can donor immune cells be engineered to fight blood cancer?